David N. Adam, MD, FRCPC

CCA Medical Research
95 Bayly Street West, Suite G-02
Ajax, Ontario, Canada
L1S 7K8
905-427-3996


Specialty: Dermatology

Dr. David Adam

Research Interests: Acne, Actinic Keratoses, Alopecia, Basal Cell Carcinoma, Black Skin Disorders, Bowen’s Disease, Cellulitis, Cosmetics, Darier’s Disease, Dermatitis, Disorders of Keratinization, Dry Skin, Folliculitis, Genital Herpes and Warts, Moles, Molluscum, Neurodermatitis, Onychomycosis, Photoaging, Pigmentary Disorders, Pigmented Lesions, Psoriasis, Rosacea, Seborrheic Dermatitis, Tinea Corporis, Tinea Cruris, Tine Pedis, Wrinkles

Dr. David Adam has been practicing Dermatology in the Greater Toronto Area since 2007. In 2012, Dr. Adam opened Baywood Dermatology, the leading center for medical dermatology in Ajax, Ontario. Dr. Adam has been involved with clinical research since 1995 and in 2009 Dr. Adam founded CCA Medical Research, where he has been Principal Investigator for clinical trials in dermatology. With CCA Medical Research and Baywood Dermatology, Dr. Adam will continue to provide patients with leading edge medical care.

Dr. Adam’s current positions include Assistant Professor in the Department of Medicine at the University of Toronto, and Dermatologist and Supervisor of Undergraduate Medical Education at St. Michael’s Hospital in Toronto.

Dr. Adam has published many peer reviewed articles on dermatological conditions, including psoriasis and malignant melanoma.

 

Click to view Dr. David Adam's Publications

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016 Dec 15; 375(24): 2335-48. Epub 2016 Sep 30. PMID: 27690741 / doi: 10.1056/NEJMoa1610020

Alavi A, Adam DN, Alhusayen R, Boucier M, Brassard A, Coutts P, Gooderham M, Gulliver W, Hong CH, Lynde C, Marcoux D, Papp K, Poulin Y, Sibbald RG, Shear NH. Definition of moderate to severe hidradenitis suppurativa: a position paper by the Canadian hidradenitis suppurativa foundation (CHSF). J Cutan Med Surg 2016 Nov; 20(6): 613-15. PMID: 27821541 / doi: 10.1177/1203475416660296

Chan LY, Adam RS, Adam DN. Localized topical steroid use and central serous retinopathy. J Dermatolog Treat 2016 Oct; 27(5): 4256. Epub 2016 Jan 29. PMID: 26822912 / doi: 10.3109/09546634.2015.1136049

Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. J Cutan Med Surg 2016 Sep; 20(5): 375-431. Epub 2016 Jul 15. PMID: 27421294 / doi: 10.1177/1203475416655705

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016 Jul 28; 375(4): 345-56. Epub 2016 Jun 8. PMID: 27299809 / doi: 10.1056/MEJMoa1512711

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015 Oct; 173(4): 949-61. PMID: 26149717 / doi: 10.1111/bjd.14018

Rajakulendran T, Adam DN. Spotlight on pembrolizumab in the treatment of advanced melanoma. Drug Des Devel Ther 2015 Jun 4; 9:2883-6. eCollection 2015. PMID: 26082618 / doi: 10.2147/DDDT.S78036

Chen JYF, Stroz MJ, Adam DN. Tinea pedis presenting as asymmetric purpuric papules on the sole of the foot: A case report. Case Rep Dermatol 2015 Mar 5; 7(1):36-8. eCollection 2015 Jan-Apr. PMID: 25873874 / doi: 10.1159/000380848

Tan J, Humphrey S, Vender R, Barankin B, Gooderham M, Kerrouche N, Audibert F, Lynde C; POWER study group. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol 2014 Dec; 171(6):1508-16. Epub 2014 Oct 28. PMID: 24934963 / doi: 10.1111/bjd.13191

Rajakulendran T, Adam DN. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma. Int J Dermatol 2014 Dec; 53(12): 1428-33. Epub 2014 Oct 14. PMID: 25311997 / doi: 10.1111/ijd.12724

Pavenski K, Vandenberghe H, Jakubovic H, Adam DN, Garvey B, Streutker CJ. Plasmapheresis and steroid treatment of levamisole-induced vasculopathy and associated skin necrosis in crack/cocaine users. J Cutan Med Surg 2013 Mar-Apr; 17(2):123-8. PMID: 23582166

Velykoredko Y, Adam DN. Painful blisters on the hand. BMJ 2013 Mar 26; 346:f1753. PMID: 23532869 / doi: 10.1136/bmj.f1753

Jakubovic BD, Sawires HF, Adam DN. Occult cause of paraneoplastic acanthosis nigricans in a patient with known breast dcis: Case and review. Curr Oncol 2012 Aug; 19(4):e299-302. PMID: 22876161

Vale R, Adam DN. Idiopathic aquagenic wrinkling of the palms in sisters. J Dermatol 2012 May; 39(5): 471-2. Epub 2011 Oct 20. PMID: 22011022 / doi: 10.1111/j.1346-8138.2011.01387.x

Greenspoon J, Herrmann N, Adam DN. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature. CNS Drugs 2011 Jul 1; 25(7):575-583. PMID: 21623641 / doi: 10.2165/11592230-000000000-00000

Bacher J, Assaad D, Adam DN. Pyogenic granuloma of the foot with satellitosis: a role for conservative management. J Cutan Med Surg 2011 Jan-Feb; 15(1):58-60. PMID: 21291657

Xi NN, Assaad D, Adam DN. A rare variant of a common nodule. McGill J Med 2010; 13(1):16-17. PMID: 22363179

Adam DN, Beleznay KM, Randhawa RS, Marton M, Zhou Y. Review of intravascular lymphoma with a report of treatment with allogenic peripheral blood stem cell transplant. Cutis 2008; 82(4):267-272. PMID: 19055170

Zhang J*, Adam DN*, Stebbing E, Gerbrandt J, Lui H, Shapiro J, Zhou Y. Efficacy of a day-care program in the treatment of psoriasis. J Cutan Med Surg 2008; 12(5):211-216. PMID: 18845089 *first authorship shared

Adam DN, Cohen PD, Sibbald RG, Ghazarian D. Necrolytic migratory erythema: case report and clinical review. J Cutan Med Surg 2003; 7(4):333-338. PMID: 14738101

Adam DN. Malignant melanoma: diagnosis and treatment. University of Toronto Medical Journal 2002; 79(2):94-99.

Adam DN. Sherlock Adam. The Schoch Letter 2001; 51(10):37.

Adam D, Adam J, Price H. An analysis of an inflammatory bowel disease practice in an urban community hospital. Can J Gastroenterol 2000; 14(6):483-488.

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.

Login